CTOs on the Move

Meiogen Biotechnology Corporation

www.meiogen.com

 
Meiogen Biotechnology Corporation is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million
  • www.meiogen.com
  • 100 Cummings Ctr Ste 431a
    Beverly, MA USA 01915
  • Phone: 978.927.0878

Executives

Name Title Contact Details

Similar Companies

XenoPort

XenoPort, Inc. is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Infectious Disease Research Institute

IDRI is a nonprofit biotech organization taking a comprehensive approach to develop new solutions for infectious disease. We combine the high-quality science of a research or academic organization with the product development capabilities of a life science company, including an onsite GMP manufacturing facility.

Marlon Ramos at Frange Blue-Hairstylist

Marlon Ramos at Frange Blue-Hairstylist is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gradalis

Gradalis, Inc. is a fully integrated biotechnology company based in Dallas, Texas that focuses on the development, manufacturing, and commercialization of drugs, vaccines, tools, and diagnostics primarily in the area of cancer. Gradalis has its own GMP manufacturing facility along with highly skilled technical leadership and staff and a strategic partnership with Mary Crowley Cancer Research Centers for clinical development of Gradalis products. The Company has two primary platforms, one centered on personalized autologous vaccines and a second focused on bifunctional short hairpin RNA (shRNA) to enable specific protein knockdown. In addition. Gradalis has numerous partnerships and joint ventures that provide it with access to other cutting edge clinical and pre-clinical stage programs.  

Nohla Therapeutics

Nohla Therapeutics is a cellular therapy company driven to provide leading off the shelf therapies for patients with critical diseases. Nohla’s first product is a universal donor cell therapy targeting hematopoietic recovery and chemotherapy induced neutropenia, and is being extended to treat a range of other medical indications. This and other products in the pipeline are based on a unique umbilical cord blood expansion platform developed at the Fred Hutchinson Cancer Research Center